Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer

 Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer

Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer

Shots:

  • Linnaeus will conduct 6 additional P-II cohorts evaluating LNS8801 + Keytruda in several cancer indications while the companies are currently evaluating the combination in patients who had previously responded to PD-1/L1 therapy and also LNS8801 as a monothx in patients unable to tolerate PD-1/L1 therapy due to serious immune-related AEs
  • The companies will further evaluate the combination in patients with selected advanced solid tumors, based on promising preliminary safety, PD, and efficacy data
  • LNS8801 (PO) is a bioavailable small molecule that is a highly specific & potent agonist of the GPER and ongoing P-I/IIa study demonstrates target engagement, c-Myc oncoprotein depletion, and clinical beneficial for advanced cancer patients

Click here to­ read full press release/ article | Ref: PR Newswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post